



CHILDREN'S
CLINICAL CARE, LLC

Children's Clinical Care, LLC
445 2nd St.
Suite 210
Lake Oswego, OR 97034

February 27, 2019

HOUSE HEALTH CARE COMMITTEE - MANDATORY VACCINATION BILL HB 3063

Chief Sponsors: Representative Greenlick, Helt, Mitchell, Schouten, Wilde, Senator Thomsen

Regular Sponsors: Representative Doherty, Prusak, Williams, Senator Wagner

STRONG OPPOSITION HB 3063 - MANDATORY VACCINES

Dear Representatives Greenlick, Helt, Mitchell, Schouten, Wilde, Senator Thomsen and Members of the House Healthcare Committee,

My name is Lauren Corder and I am the clinical director of Children's Clinical Care, LLC, in Lake Oswego, Ore. At Children's Clinical Care, we provide cognitive-behavioral therapies to children and families. In particular, we specialize in treating children with neurocognitive disorders. As a result of my work, I have seen a wide variety of disorders, not yet well understood in both the medical research and the general public. What is known is that vaccines may have a role in the development of autoimmune disorders and contribute to neurotoxicity. As a result, imposing mandatory vaccines on children and families without a full understanding of the emerging research is irresponsible at best, and dangerous at worst. Attached are three letters from researchers explaining their position, which is supported with published, peer-reviewed journal articles. Please take the time to read these letters before voting no for a bill that would force families to endanger their children.

Sincerely,

Lauren Corder, MA, LPC
OR State License #: C4689
NPI #: 1972706539



a place of mind
THE UNIVERSITY OF BRITISH COLUMBIA

Faculty of Medicine
Department of Ophthalmology
& Visual Sciences
Shaw Laboratory
828 West 10th Avenue, Room 386
Vancouver, BC Canada V5Z 1L8

June 24, 2017

United States Department of Health & Human Services
National Institutes of Health
Food & Drug Administration
Centers for Disease Control & Prevention
200 Independence Avenue, S.W.
Washington, D.C. 20201

Phone 604 875 4111 Local 68375
Fax 604 875 4376
www.neuraldynamicsubc.ca

Re: *Aluminum Adjuvants*

Dear Directors:

I am writing to you in regard to aluminum adjuvants in vaccines. This subject is one my laboratory works on intensively and therefore one where I feel that I have some expertise. In particular, we have studied the impact of aluminum adjuvants in animal models of neurological disease, including autism spectrum disorder (ASD). Our relevant studies on the general topic of aluminum neurotoxicity in general and specifically in regard to adjuvants are cited below.

These studies and the broader existing literature regarding aluminum toxicity, lead almost invariably to the conclusion that aluminum in any chemical form is always neurotoxic when administered to humans. Further, I am convinced that aluminum adjuvants in vaccines may contribute to neurological disorders across the lifespan. In adults, such adjuvant may induce macrophagic myofasciitis, a disease with neuropathological aspects. In children, there is growing evidence that aluminum adjuvants may disrupt developmental processes in the central nervous system and therefore contribute to ASD in susceptible children.


Despite the foregoing, the safety of aluminum adjuvants in vaccines has not been properly studied in humans even though, pursuant to the recommended vaccine schedule published by the Centers for Disease Control (CDC), a baby may be injected with up to 3,675 micrograms of aluminum adjuvant by six months of age.

In regard to the above, it is my belief that the CDC's claim on its website that "Vaccines Do Not Cause Autism" is wholly unsupported. Given this, I remain convinced that much more research on the role of aluminum adjuvant in vaccines and neurological disorders, including ASD, is warranted and should be a research priority for the NIH and other funding bodies.

Yours sincerely,

Christopher A. Shaw, Ph.D
Professor
Dept. of Ophthalmology and Visual Sciences
University of British Columbia
828 W. 10th Ave.
Vancouver, British Columbia
Canada, V5Z1M9
Tel: 604-875-4111 (ext. 68373)
Email: cashawlab@gmail.com





Tel: 01782 734080
Fax: 01782 712378
e-mail: c.exley@keele.ac.uk
<http://www.keele.ac.uk/aluminium>

June 15, 2017

United States Department of Health & Human Services
National Institutes of Health
Food & Drug Administration
Centers for Disease Control & Prevention
200 Independence Avenue, S.W.
Washington, D.C. 20201

Re: *Aluminum Adjuvants*

Dear Directors:

I am an expert in the field of aluminum adjuvants and aluminum toxicity. I have been working in this field for more than 30 years during which time I have written in excess of 150 peer-reviewed scientific publications on this subject.

I strongly support the contention that aluminum adjuvants in vaccines may have a role in the etiology of autism spectrum disorder (ASD). My view is founded on a significant and burgeoning body of peer-reviewed scientific evidence which makes the link between ASD and exposure to aluminum through vaccinations and other sources. Examples of this literature from my own group are detailed below and I urge the HHS to take them into consideration in forming any future opinion on the safety of aluminum adjuvants in vaccines.

The Center for Disease Control's claim on its website that "Vaccines Do Not Cause Autism" is unsupported with respect to aluminum adjuvants and this claim stifles the important research to determine the safety of aluminum adjuvants used in vaccines. As an expert in the field of aluminum adjuvants and aluminum toxicity I solemnly declare that more research on the role of aluminum adjuvant in vaccines and neurological disorders, including ASD, is essential and urgently required.

Telephone number +44 (01782) 584211
Fax +44 (01782) 712378

Keele University, Staffordshire, ST5 5BG United Kingdom
Telephone number +44 (01782) 621111 <http://www.keele.ac.uk>

Yours faithfully



Christopher Exley PhD
Professor in Bioinorganic Chemistry

Honorary Professor, University of the Highlands and Islands

List of Recent, Relevant and Significant Publications From Our Group

Exley C, Siesjö P & Eriksson H (2010) The immunobiology of aluminium adjuvants: how do they really work? *Trends in Immunology* 31, 103-109.

Exley C and House E (2011) Aluminium in the human brain. *Monatshefte für Chemie - Chemical Monthly* 142, 357-363.

House E, Esiri M, Forster G, Ince PG and Exley C (2012) Aluminium, iron and copper in human brain tissues donated to the medical research council's cognitive function and ageing study. *Metallomics* 4, 56-65.

Exley C (2011) Aluminium-based adjuvants should not be used as placebos in clinical trials. *Vaccine* 29, 9289.

Exley C (2012) When an aluminium adjuvant is not an aluminium adjuvant used in human vaccination programmes. *Vaccine* 30, 2042.

Exley C (2012) The coordination chemistry of aluminium in neurodegenerative disease. *Coordination Chemistry Reviews* 256, 2142-2146.

Exley C, House E, Polwart A and Esiri MM (2012) Brain burdens of aluminium, iron and copper and their relationships with amyloid beta pathology in 60 human brains. *Journal of Alzheimer's Disease* 31, 725-730.

Davenward S, Bentham P, Wright J, Crome P, Job, D, Polwart A and Exley C (2013) Silicon-rich mineral water as a non-invasive test of the 'aluminium hypothesis' in Alzheimer's disease. *Journal of Alzheimer's Disease* 33, 423-430.

Khan Z, Combadière C, Authier FJ, Itier V, Lux F, Exley C, Mahrouf-Yorgov M, Decrouy X, Moretto P, Tillement O, Gherardi RK, and Cadusseau J (2013) Slow CCL2-dependent translocation of biopersistent particles from muscle to brain. *BMC Medicine* 11:99.

Exley C (2013) Human exposure to aluminium. *Environmental Science: Processes and Impacts* 15, 1807-1816.

Ohlsson L, Exley C, Darabi A, Sandén E, Siesjö P and Eriksson H (2013) Aluminium based adjuvants and their effects on mitochondria and lysosomes of phagocytosing cells. *Journal of Inorganic Biochemistry* 128, 229-236.

Exley C (2014) Aluminium adjuvants and adverse events in sub-cutaneous allergy immunotherapy. *Allergy, Asthma and Clinical Immunology* 10, 4.

Exley C and Vickers T (2014) Elevated brain aluminium and early onset Alzheimer's disease in an individual occupationally exposed to aluminium: a case report. *Journal of Medical Case Reports* 8,41.

Exley C (2014) What is the risk of aluminium as a neurotoxin? *Expert Review of Neurotherapeutics* 14, 589-591.

Mold M, Eriksson H, Siesjö P, Darabi A, Shardlow E and Exley C (2014) Unequivocal identification of intracellular aluminium adjuvant in a monocytic THP-1 cell line. *Scientific Reports* 4, 6287.

Telephone number +44 (01782) 584211
Fax +44 (01782) 712378

Keele University, Staffordshire, ST5 5BG United Kingdom
Telephone number +44 (01782) 621111 <http://www.keele.ac.uk>

June 15, 2017

United States Department of Health & Human Services
National Institutes of Health
Food & Drug Administration
Centers for Disease Control & Prevention
200 Independence Avenue, S.W.
Washington, D.C. 20201

Re: *Aluminum Adjuvants*

Dear Directors:

I am an expert in the field of aluminum adjuvants toxicity in humans and animal models. I have been working in this field since the initial description of the AI vaccine-induced macrophagic myofasciitis in 1998. Since that time I have written 40 peer-reviewed scientific publications and one book on this subject.

I strongly support the contention that aluminum adjuvants in vaccines may have a role in the etiology of autism spectrum disorder (ASD). My view is founded on a significant and burgeoning body of peer-reviewed scientific evidence which makes the link between ASD and exposure to aluminum through vaccinations and other sources. Examples of this literature from my own group are detailed below and I urge the HHS to take them into consideration in forming any future opinion on the safety of aluminum adjuvants in vaccines.

The Center for Disease Control's claim on its website that "Vaccines Do Not Cause Autism" is unsupported with respect to aluminum adjuvants and this claim stifles the important research to determine the safety of aluminum adjuvants used in vaccines. As an expert in the field of aluminum adjuvants and aluminum toxicity I solemnly declare that more research on the role of aluminum adjuvant in vaccines and neurological disorders, including ASD, is essential and urgently required.

Yours very sincerely



Romain K. Gherardi
Professor, Neuromuscular Pathology Expert Centre
University Paris-Est, INSERM U955-E10,
Henri Mondor hospital, Créteil France
Contact at the hospital
Tel 00 (33) 1 49812746
romain.gherardi@hmn.aphp.fr

— UMR U955 INSERM / UPEC

Team 10

— « Biology of the neuromuscular system »

Fred Relaix, director

— François Jérôme Authier, co-director

Romain Gherardi, former director

Tél. +33 (0)1 49 81 27 42

Fax. +33 (0)1 49 81 27 33

romain.gherardi@inserm.fr